BVS Valuation

Bioventus Inc

Add to Watchlist

Advanced Chart

7.480

+0.1(1.355%)1D

BVS Relative Valuation

BVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BVS is overvalued; if below, it's undervalued.

Historical Valuation

Bioventus Inc (BVS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.38 is considered Overvalued compared with the five-year average of 22.85. The fair price of Bioventus Inc (BVS) is between 2.78 to 3.85 according to relative valuation methord. Compared to the current price of 7.38 USD , Bioventus Inc is Overvalued By 91.81%.

Relative Value

Fair Zone

2.78-3.85

Current Price：7.38

91.81%

Overvalued

9.52

Trailing

Forward

6.68

EV/EBITDA

Bioventus Inc. (BVS) has a current EV/EBITDA of 6.68. The 5-year average EV/EBITDA is 8.95. The thresholds are as follows: Strongly Undervalued below 4.90, Undervalued between 4.90 and 6.92, Fairly Valued between 10.98 and 6.92, Overvalued between 10.98 and 13.01, and Strongly Overvalued above 13.01. The current Forward EV/EBITDA of 6.68 falls within the Undervalued range.

7.58

EV/EBIT

Bioventus Inc. (BVS) has a current EV/EBIT of 7.58. The 5-year average EV/EBIT is 11.42. The thresholds are as follows: Strongly Undervalued below 4.09, Undervalued between 4.09 and 7.75, Fairly Valued between 15.08 and 7.75, Overvalued between 15.08 and 18.75, and Strongly Overvalued above 18.75. The current Forward EV/EBIT of 7.58 falls within the Undervalued range.

7.38

Bioventus Inc. (BVS) has a current PS of 7.38. The 5-year average PS is 0.94. The thresholds are as follows: Strongly Undervalued below -0.40, Undervalued between -0.40 and 0.27, Fairly Valued between 1.61 and 0.27, Overvalued between 1.61 and 2.29, and Strongly Overvalued above 2.29. The current Forward PS of 7.38 falls within the Strongly Overvalued range.

5.05

P/OCF

Bioventus Inc. (BVS) has a current P/OCF of 5.05. The 5-year average P/OCF is 3.20. The thresholds are as follows: Strongly Undervalued below -41.39, Undervalued between -41.39 and -19.09, Fairly Valued between 25.50 and -19.09, Overvalued between 25.50 and 47.80, and Strongly Overvalued above 47.80. The current Forward P/OCF of 5.05 falls within the Historic Trend Line -Fairly Valued range.

4.87

P/FCF

Bioventus Inc. (BVS) has a current P/FCF of 4.87. The 5-year average P/FCF is 5.83. The thresholds are as follows: Strongly Undervalued below -10.93, Undervalued between -10.93 and -2.55, Fairly Valued between 14.22 and -2.55, Overvalued between 14.22 and 22.60, and Strongly Overvalued above 22.60. The current Forward P/FCF of 4.87 falls within the Historic Trend Line -Fairly Valued range.

Bioventus Inc (BVS) has a current Price-to-Book (P/B) ratio of 2.98. Compared to its 3-year average P/B ratio of 2.35 , the current P/B ratio is approximately 26.79% higher. Relative to its 5-year average P/B ratio of 2.54, the current P/B ratio is about 17.25% higher. Bioventus Inc (BVS) has a Forward Free Cash Flow (FCF) yield of approximately 0.11%. Compared to its 3-year average FCF yield of 0.46%, the current FCF yield is approximately -76.53% lower. Relative to its 5-year average FCF yield of 1.42% , the current FCF yield is about -92.36% lower.

2.98

P/B

Median3y

2.35

Median5y

2.54

0.11

FCF Yield

Median3y

0.46

Median5y

1.42

Competitors Valuation Multiple

The average P/S ratio for BVS's competitors is 11.11, providing a benchmark for relative valuation. Bioventus Inc Corp (BVS) exhibits a P/S ratio of 7.38, which is -33.58% above the industry average. Given its robust revenue growth of -0.23%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Organogenesis Holdings Inc

Semler Scientific Inc

Cytek Biosciences Inc

Performance Decomposition

Market capitalization of BVS decreased by 39.95% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 20.50 to 48.05.

The secondary factor is the Revenue Growth, contributed -0.23%to the performance.

Overall, the performance of BVS in the past 1 year is driven by P/E Change. Which is more unsustainable.

-0.23%

138.96M → 138.65M

Revenue Growth

-174.10%

-3.90 → 2.89

Margin Expansion

134.38%

20.50 → 48.05

P/E Change

-39.95%